You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: February 28, 2024

Anakinra - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for anakinra
Recent Clinical Trials for anakinra

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Istituto Giannina GasliniPhase 3
Oxford University Clinical Research Unit, VietnamPhase 2
Hospital for Tropical Diseases, Ho Chi Minh City, VietnamPhase 2

See all anakinra clinical trials

Recent Litigation for anakinra

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AbbVie Inc. v. Hetero USA, Inc.2023-11-20
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD.2023-01-19
AMGEN INC. v. APOTEX INC.2022-06-14

See all anakinra litigation

PTAB Litigation
PetitionerDate
2015-06-02
2012-09-25

See all anakinra litigation

Pharmacology for anakinra
Mechanism of ActionInterleukin 1 Receptor Antagonists
Established Pharmacologic ClassInterleukin-1 Receptor Antagonist
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for anakinra Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for anakinra Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Swedish Orphan Biovitrum Ab (publ) KINERET anakinra Injection 103950 ⤷  Try a Trial 2008-12-24 Company disclosures
Swedish Orphan Biovitrum Ab (publ) KINERET anakinra Injection 103950 ⤷  Try a Trial 2020-07-29 Company disclosures
Swedish Orphan Biovitrum Ab (publ) KINERET anakinra Injection 103950 ⤷  Try a Trial 2022-02-22 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for anakinra Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for anakinra

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
10299011 Germany ⤷  Try a Trial PRODUCT NAME: KINERET(R) (WIRKSAMER BESTANDTEIL ANAKINRA); REGISTRATION NO/DATE: EU/1/02/203/001-004 20020308
2002C/023 Belgium ⤷  Try a Trial PRODUCT NAME: ANAKINRA; REGISTRATION NO/DATE: EU/1/02/203/001 20020311
SZ 23/2002 Austria ⤷  Try a Trial PRODUCT NAME: ANAKINRA
23/2002 Austria ⤷  Try a Trial PRODUCT NAME: ANAKINRA; REGISTRATION NO/DATE: EU/1/02/203/001- EU/1/02/203/004 20020308
SPC/GB02/026 United Kingdom ⤷  Try a Trial PRODUCT NAME: ANAKINRA (ALSO KNOWN AS HUMAN IL-1RA); REGISTERED: UK EU/1/02/203/001 20020308; UK EU/1/02/203/002 20020308; UK EU/1/02/203/003 20020308; UK EU/1/02/203/004 20020308
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.